Authors: Akkerhuis, KM van den Brand, MJBM van der Zwaan, C Peels, HOJ Suryapranata, H van der Wieken, LR Stibbe, J Hoffmann, J Baardman, T Deckers, JW Simoons, ML

Citation: Km. Akkerhuis et al., Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty, HEART, 85(4), 2001, pp. 444-450

Authors: O'Neill, WW Serruys, P Knudtson, M van Es, GA Timmis, GC van der Zwaan, C Kleiman, J Gong, JJ Roecker, EB Dreiling, R Alexander, J Anders, R

Citation: Ww. O'Neill et al., Long-term treatment with a platelet glycoprotein-receptor antagonist afterpercutaneous coronary revascularization., N ENG J MED, 342(18), 2000, pp. 1316-1324

Authors: O'Neill, WW Serruys, P Knudtson, M Van Es, GA Timmis, GC van der Zwaan, C Kleiman, J Barker, K Dreiling, R Hubbard, R Alexander, J Anders, R

Citation: Ww. O'Neill et al., Design and objectives of the Evaluation of Oral Xemilofiban in ControllingThrombotic Events (EXCITE) study, J INTERV CA, 12(2), 1999, pp. 109-115

Authors: Simoons, ML Boersma, E van der Zwaan, C Deckers, JW

Citation: Ml. Simoons et al., The challenge of acute coronary syndromes, LANCET, 353, 1999, pp. SII1-SII4